Will the approval of Inflectra be a biosimilar adoption tipping point?

via BioPharma Dive

June 10, 2016

By Nicole Gray

The approval of Inflectra™ (infliximab) in April was a tipping point for biosimilars in the U.S. Inflectra was the first complex monoclonal antibody biosimilar to be approved in in the U.S., a sign that regulators are comfortable with the biosimilar approval path, Pfenex Inc. CEO Bert Liang told BioPharma Dive. Knowledge of and experience with biosimilars in other parts of the world is impacting the U.S. market, and that there is a growing sense of momentum and increased demand in the space.

Read full article